These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27275747)

  • 1. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.
    Levitsky J; Miller J; Huang X; Gallon L; Leventhal JR; Mathew JM
    PLoS One; 2016; 11(6):e0156535. PubMed ID: 27275747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans.
    Levitsky J; Miller J; Huang X; Chandrasekaran D; Chen L; Mathew JM
    Transplantation; 2013 Oct; 96(8):689-96. PubMed ID: 23883971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.
    Levitsky J; Gallon L; Miller J; Tambur AR; Leventhal J; Flaa C; Huang X; Sarraj B; Wang E; Mathew JM
    Transplantation; 2011 Jan; 91(2):199-206. PubMed ID: 21239962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
    Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
    Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
    Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM
    Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
    Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance - an experimental study.
    Katsumata H; Miyairi S; Ikemiyagi M; Hirai T; Fukuda H; Kanzawa T; Ishii R; Saiga K; Ishii Y; Omoto K; Okumi M; Yokoo T; Tanabe K
    Transpl Int; 2019 Apr; 32(4):443-453. PubMed ID: 30561097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic Drug-Drug Interaction on Human Peripheral Blood Mononuclear Cells Between Everolimus and Tacrolimus at the Therapeutic Concentration Range in Renal Transplantation.
    Okihara M; Takeuchi H; Akiyama S; Yoshinaga R; Osato S; Akashi I; Kihara Y; Konno O; Iwamoto H; Oda T; Tanaka S; Unezaki S; Hirano T
    Ann Transplant; 2021 Feb; 26():e928817. PubMed ID: 33633104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable effects of alemtuzumab on allospecific regulatory T-cell generation.
    Levitsky J; Leventhal JR; Miller J; Huang X; Chen L; Chandrasekaran D; Tambur AR; Mathew JM
    Hum Immunol; 2012 Feb; 73(2):141-9. PubMed ID: 22154724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: an in-vitro study in healthy humans.
    Fanigliulo D; Lazzerini PE; Capecchi PL; Ulivieri C; Baldari CT; Laghi-Pasini F
    Int Immunopharmacol; 2015 Feb; 24(2):276-284. PubMed ID: 25536542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells.
    Traitanon O; Mathew JM; La Monica G; Xu L; Mas V; Gallon L
    PLoS One; 2015; 10(6):e0129658. PubMed ID: 26087255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Fernandes FB; Casarini DE; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Feb; 23(1):137-45. PubMed ID: 19267777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis.
    Vukmanovic-Stejic M; McQuaid A; Birch KE; Reed JR; Macgregor C; Rustin MH; Akbar AN
    Br J Dermatol; 2005 Oct; 153(4):750-7. PubMed ID: 16181456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil.
    Miroux C; Morales O; Ouaguia L; Aoudjehane L; Boleslawski E; Pancré V; de Launoit Y; Calmus Y; Conti F; Delhem N
    Transplant Proc; 2012 Nov; 44(9):2834-9. PubMed ID: 23146536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.